DB
AVXL icon

Dmitry Balyasny’s Anavex Life Sciences AVXL Stock Holding History

Dmitry Balyasny’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-390,000
Closed -$3.6M – 2904
2025
Q2 		$3.6M Hold
390,000
– – 0.01% 1448
2025
Q1 		$3.35M Buy
+390,000
New +$3.68M 0.01% 1445

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
NL
NWAM LLC Mercer Island, Washington $2B AUM 34.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Dmitry Balyasny's AVXL Position: Q3 2025 in Review

Dmitry Balyasny sold out of Anavex Life Sciences (AVXL) in Q3 2025, closing a stake of 245,624 shares — an estimated $2.26M sold.

Dmitry Balyasny first reported a position in AVXL in Q1 2016 and held it in 12 quarters. The position peaked at $2.26M in Q2 2025. 186 funds tracked by Wall St. Rank hold AVXL as of Q3 2025.

  • Dmitry Balyasny reported no remaining Anavex Life Sciences position as of Q3 2025 after selling out during the quarter.
  • Dmitry Balyasny sold 245,624 Anavex Life Sciences shares in Q3 2025, an estimated $2.26M.
  • Dmitry Balyasny first reported a position in Anavex Life Sciences in Q1 2016 and held it in 12 quarters.
  • Dmitry Balyasny's Anavex Life Sciences position peaked at $2.26M in Q2 2025.
  • 186 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q3 2025.

Based on Balyasny Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.